Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID-C: Certolizumab Pegol in Chinese RA patients
NCT02151851Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2014
- Primary completion
- Jun 2016
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Certolizumab Pegol + Methotrexate with Placebo + Methotrexate (2 arms). Primary endpoint: American College of Rheumatology 20% Response Criteria at 24 weeks. Started Jul 2014; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02151851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151851.